CANNAINVESTOR Magazine December / January 2016 - Page 112

Israel currently boasts 26,000 patients licensed under its medical cannabis program. Their medicine is grown by one of eight federally licensed growers. That number will grow, as will the patient base as the roll out of Israel’s new medical cannabis reform takes hold. The current indications for medical cannabis use covered in Israel are: Crohn’s disease, Ulcerative Colitis, Chronic Pain, Neurological Disorders such as Parkinson’s disease, Tourette’s Syndrome, Epilepsy, Multiple Sclerosis, PTSD, certain types of cancer, infectious disease like HIV/AIDS, and palliative care.

It is Israel’s positive regulatory environment, commitment to scientific progress and that has allowed for such a wide foundation of research and development to grow and drive data beyond the the noise and pressures of a recreational market.

If you’re interested in learning more about the data and innovation that drives this industry across the globe, if you’re interested in tuning into the scene beyond the noise of the recreational market, then you’re definitely going to want to be a part of CannaTech 2017 hosted for the third year in a row this March 20-22 in Tel Aviv.

We’ll be very happy to show you around.